ArticleCurrent drug delivery2026
Hyaluronic Acid-Modified Nanoparticles Loaded with Cabazitaxel: A Promising Nanomedicine for Malignant Prostate Tumors.
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProstate cancer is the most common cancer among men globally. The firstline drug, cabazitaxel (CTX), has significant side effects such as neutropenia and anemia. To address this, we aimed to develop hyaluronic acid (HA)-modified human serum albumin (HSA)-loaded CTX nanoparticles (HA-CTX NPs) to target prostate tumors with enhanced efficacy and reduced toxicity.
methodsHA-CTX NPs were synthesized via a self-assembly method and optimized using unidirectional and response surface analyses. The NPs were characterized by particle size, zeta potential, and morphology. In vitro experiments evaluated the pharmacokinetics, cytotoxicity, and cellular uptake in prostate cancer cells with high CD44 expression and in HepG-2 cells with low CD44 expression. In vivo anti-tumor efficacy and biosafety were assessed using tumor-bearing models.
resultsThe optimized HA-CTX NPs achieved an encapsulation efficiency of 89.2 ± 1.3%. Disulfide bonds enabled rapid drug release in the tumor microenvironment with high glutathione levels. In vitro studies showed significant cytotoxicity and targeting ability for prostate cancer cells. In vivo assays demonstrated a tumor inhibition rate of 85.31% with good biosafety. DISCUSSION: HA-CTX NPs exhibited superior anti-tumor efficacy and biosafety compared to Jevtana ®. The targeting ability was attributed to the high CD44 expression in prostate cancer cells. The rapid drug release in the tumor microenvironment contributed to the enhanced therapeutic effect. Limitations include the need for further long-term safety studies.
conclusionHA-CTX NPs represent a promising nanomedicine for prostate tumor treatment, offering improved efficacy and reduced side effects compared to conventional CTX formulations.
Indexed as
Identifiers
41540521What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.